Get started
Author

J.M. Bauml

Observed name: J. Bauml
OpenAlex ID: A5039701508
Amivantamab plus lazertinib versus osimertinib in first-line EGFR-mutant advanced non-small-cell lung cancer with biomarkers of high-risk disease: a secondary analysis from MARIPOSA
2024 · E. Felip, B.C. Cho, et al. · Annals of Oncology · 114
LBA55 Mechanisms of acquired resistance to first-line amivantamab plus lazertinib versus osimertinib in patients with EGFR-mutant advanced non-small cell lung cancer: An early analysis from the phase III MARIPOSA study
2024 · B. Besse, S-H. Lee, et al. · Annals of Oncology · 53
PDF
LBA54 Amivantamab plus chemotherapy vs chemotherapy in EGFR-mutated, advanced non-small cell lung cancer after disease progression on osimertinib: Second interim overall survival from MARIPOSA-2
2024 · S. Popat, K.L. Reckamp, et al. · Annals of Oncology · 20
PDF
10MO: Preventing moderate to severe dermatologic adverse events in first-line EGFR-mutant advanced NSCLC treated with amivantamab plus lazertinib: Early success of the COCOON trial
2025 · N. Girard, W. Li, et al. · Journal of Thoracic Oncology · 17
PDF
Letter to the Editor regarding ‘Correspondence to: Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study’ by Moik F, Riedl JM, and Ay C
2023 · A. Passaro, J. Wang, et al. · Annals of Oncology · 16
PDF
P3.12D.04 Enhanced vs Standard Dermatologic Management with Amivantamab-Lazertinib in Advanced NSCLC: Phase 2 COCOON Study
2024 · B.C. Cho, N. Girard, et al. · Journal of Thoracic Oncology · 8
19P Mortality among EGFR-mutated advanced NSCLC patients after frontline osimertinib treatment: A real-world, US attrition analysis
2023 · N. Girard, N. Leighl, et al. · Journal of Thoracic Oncology · 7
PDF
P1.16-01 Amivantamab and Lazertinib in Treatment-Naive EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)
2022 · B.C. Cho, S.-H. Lee, et al. · Journal of Thoracic Oncology · 7
MA07.04 Amivantamab and Lazertinib in Combination with Platinum-Based Chemotherapy in Relapsed/Refractory EGFR-mutant NSCLC
2022 · M.E. Marmarelis, S.-H. Lee, et al. · Journal of Thoracic Oncology · 6
PDF
MA12.08 Preventing Infusion-Related Reactions with Intravenous Amivantamab: Primary Results from SKIPPirr, a Phase 2 Study
2024 · G. Lopes, A.I. Spira, et al. · Journal of Thoracic Oncology · 5
PDF
MA13.06 Amivantamab, Lazertinib Plus Platinum-based Chemotherapy in EGFR-mutated Advanced NSCLC: Updated Results from CHRYSALIS-2
2023 · S.-H. Lee, B.C. Cho, et al. · Journal of Thoracic Oncology · 4
PDF
322MO Amivantamab in combination with lazertinib in patients with atypical epidermal growth factor receptor (EGFR) mutations excluding exon 20 insertion mutations: Initial results from CHRYSALIS-2
2022 · B.C. Cho, Y. Wang, et al. · Annals of Oncology · 4
398TiP MARIPOSA-2: Randomized phase III study of amivantamab + lazertinib + chemotherapy vs chemotherapy alone in EGFR-mutant NSCLC after osimertinib failure
2022 · J. Wang, R. Garcia Campelo, et al. · Annals of Oncology · 4
OA02.05 Lazertinib vs Osimertinib in 1L EGFR-Mutant Advanced NSCLC: A Randomized, Double-Blind, Exploratory Analysis from MARIPOSA
2024 · S.-H. Lee, B.C. Cho, et al. · Journal of Thoracic Oncology · 3
PDF
P1.15-07 Phase II Study of Pembrolizumab and Itacitinib for First Line Treatment of Metastatic NSCLC Expressing PD-L1
2022 · M.E. Marmarelis, D. Mathew, et al. · Journal of Thoracic Oncology · 3
P3.12.46 Enhanced vs Standard Dermatologic Management With Amivantamab-Lazertinib in EGFRm Advanced NSCLC: The COCOON Global RCT
2025 · B.C. Cho, W. Li, et al. · Journal of Thoracic Oncology · 1
EP.12H.02 Amivantamab, An EGFR-MET Bispecific Antibody, with Cetrelimab, An Anti-PD-1 Antibody, In Advanced NSCLC: Phase 1/2 Polydamas
2024 · P.J. Voon, J.-L. Tan, et al. · Journal of Thoracic Oncology · 1
PDF
LBA11 Amivantamab plus chemotherapy vs chemotherapy among Asian patients with EGFR-mutant advanced NSCLC after progression on osimertinib: A MARIPOSA-2 subgroup analysis
2023 · J-Y. Shih, J. Wang, et al. · Annals of Oncology · 1
PDF
EP08.02-173 Treatment Patterns and Outcomes Among Patients With EGFR-mutant Advanced NSCLC in the Frontline and Post-Osimertinib Settings
2022 · J. Sabari, S. Pisano, et al. · Journal of Thoracic Oncology · 1
OA09.05 Subcutaneous vs Intravenous Amivantamab: Patient Satisfaction and Resource Utilization Results from the PALOMA-3 Study
2024 · M. Alexander, Y. Cheng, et al. · Journal of Thoracic Oncology
PDF
Works count: 20
Citation count: 275
H-index: 7
I10-index: 5
Year
Topic
Type